Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation

Biochemical and Biophysical Research Communications

Volumn 423, Issue 1, 2012, Pages 26-31

  Zhang, Yuan Yuan ^a   Zhou, Li Ming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Mdm2; P53; Sirt3

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SIRTUIN 3; STRESS ACTIVATED PROTEIN KINASE;

ACETYLATION; ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE REGULATION; CELL NUCLEUS; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOWN-REGULATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NAD; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SIRTUIN 3; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; MAMMALIA;

EID: 84862689176     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.053     Document Type: Article

References (39)

1. Howe H.L., Wingo P.A., Thun M.J., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst. 2001, 93:824-842.
2. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
3. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
4. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
6. Mathupala S.P., Ko Y.H., Pedersen P.L. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim. Biophys. Acta 2010, 1797:1225-1230.
7. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
8. Milne J.C., Denu J.M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 2008, 12:11-17.
9. Lombard D.B., Alt F.W., Cheng H.L., et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 2007, 27:8807-8814.
10. Ahn B.H., Kim H.S., Song S., et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105:14447-14452.
11. Hirschey M.D., Shimazu T., Goetzman E., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
12. Qiu X., Brown K., Hirschey M.D., et al. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010, 12:662-667.
13. Ashraf N., Zino S., Macintyre A., et al. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 2006, 95:1056-1061.
14. Kim H.S., Patel K., Muldoon-Jacobs K., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
15. Bell E.L., Emerling B.M., Ricoult S.J., et al. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011, 30:2986-2996.
16. Finley L.W., Carracedo A., Lee J., et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011, 19:416-428.
17. Alhazzazi T.Y., Kamarajan P., Joo N., et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117:1670-1678.
18. Chen R., Jin R., Wu L., et al. Reticulon 3 attenuates the clearance of cytosolic prion aggregates via inhibiting autophagy. Autophagy 2011, 7:205-216.
19. Lim J., Kim H.W., Youdim M.B., et al. Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy 2011, 7:51-60.
20. Bhutia S.K., Das S.K., Azab B., et al. Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24). Autophagy 2011, 7:1076-1077.
21. Wang P., Xu T.Y., Guan Y.F., et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 2009, 81:370-380.
22. Wang P., Xu T.Y., Guan Y.F., et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 2011, 69:360-374.
23. Nezis I.P., Shravage B.V., Sagona A.P., et al. Autophagy as a trigger for cell death: autophagic degradation of inhibitor of apoptosis dBruce controls DNA fragmentation during late oogenesis in Drosophila. Autophagy 2010, 6:1214-1215.
24. Zhang X., Li L., Chen S., et al. Rapamycin treatment augments motor neuron degeneration in SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Autophagy 2011, 7:412-425.
25. Wang P., Yang F.J., Du H., et al. Involvement of leptin receptor (LepRb)-STAT3 signaling pathway in brain FTO downregulation during energy restriction. Mol. Med. 2011, 17:523-532.
26. Wang P., Guan Y.F., Du H., et al. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy 2012, 8:77-87.
27. Wang P., Zhang R.Y., Song J., et al. Loss of AMP-activated protein kinase-alpha2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes 2012, 61:1051-1061.
28. + metabolism in health and disease. Trends Biochem. Sci. 2007, 32:12-19.
29. Brooks C.L., Gu W. Ubiquitination, Phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 2003, 15:164-171.
30. Kim S.C., Sprung R., Chen Y., et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 2006, 23:607-618.
31. Shi T., Wang F., Stieren E., et al. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 2005, 280:13560-13567.
32. Arif M., Senapati P., Shandilya J., et al. Protein lysine acetylation in cellular function and its role in cancer manifestation. Biochim. Biophys. Acta 2010, 1799:702-716.
33. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3:420-425.
34. Huang X.W., Zhao Q., Chen D.Z., et al. Mutations in the D-loop region of mitochondrial DNA and the ROS level in the tissue of hepatocellular carcinoma. Yi Chuan. 2005, 27:14-20.
35. Liu J., Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005, 15:36-42.
36. Sundaresan N.R., Gupta M., Kim G., et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 2009, 119:2758-2771.
37. Jing E., Emanuelli B., Hirschey M.D., et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc. Natl. Acad. Sci. USA 2011, 108:14608-14613.
38. Langley E., Pearson M., Faretta M., et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21:2383-2396.
39. Cheng H.L., Mostoslavsky R., Saito S., et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA 2003, 100:10794-10799.